Background: With the rapid, global spread of SARS-CoV-2, hospitals have become inundated with patients suffering from COVID-19. Consultation-liaison psychiatrists are actively involved in managing these patients and should familiarize themselves with how the virus and its proposed treatments can affect psychotropic management. The only FDA approved drug to treat COVID-19 is remdesivir, and other off-label medications used include chloroquine and hydroxychloroquine, tocilizumab, lopinavir/ritonavir, favipiravir, convalescent plasma therapy, azithromycin, vitamin C, corticosteroids, interferon and colchicine.
Purpose: To provide an overview of the major safety considerations relevant to clinicians who prescribe psychotropics to patients with COVID-19, both related to the illness and its proposed treatments.
Methods: In this targeted review we performed structured literature searches in PubMed to identify articles describing the impacts of COVID-19 on different organ systems, the neuropsychiatric adverse effects of treatments, and any potential drug interactions with psychotropics. The articles most relevant to this manuscript were included.
Results: COVID-19 impacts multiple organ systems, including gastrointestinal, renal, cardiovascular, pulmonary, immunological, and hematological systems. This may lead to pharmacokinetic changes that impact psychotropic medications and increase sensitivity to psychotropic-related adverse effects. Additionally, several proposed treatments for COVID-19 have neuropsychiatric effects and potential interactions with commonly used psychotropics.
Conclusion: Clinicians should be aware of the need to adjust existing psychotropics or avoid using certain medications in some COVID-19 patients. They should also be familiar with neuropsychiatric effects of medications being used to treat this disease. Further research is needed to identify strategies to manage psychiatric issues in this population.
Keywords: COVID-19; psychopharmacology; psychotropic; side effects.
© 2020 Published by Elsevier Inc. on behalf of Academy of Consultation-Liaison Psychiatry.
[Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic].Encephale. 2020 May 3:S0013-7006(20)30074-9. doi: 10.1016/j.encep.2020.04.006. Online ahead of print. Encephale. 2020. PMID: 32376004 Free PMC article. French.
An Update on Current Therapeutic Drugs Treating COVID-19.Curr Pharmacol Rep. 2020 May 11:1-15. doi: 10.1007/s40495-020-00216-7. Online ahead of print. Curr Pharmacol Rep. 2020. PMID: 32395418 Free PMC article. Review.
Pharmacotherapy in COVID-19; A narrative review for emergency providers.Am J Emerg Med. 2020 Apr 15:S0735-6757(20)30263-1. doi: 10.1016/j.ajem.2020.04.035. Online ahead of print. Am J Emerg Med. 2020. PMID: 32336586 Free PMC article. Review.
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus.Curr Med Chem. 2020 Apr 16. doi: 10.2174/0929867327666200416131117. Online ahead of print. Curr Med Chem. 2020. PMID: 32297571
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221. doi: 10.1177/2048872620922784. Epub 2020 May 6. Eur Heart J Acute Cardiovasc Care. 2020. PMID: 32372695 Free PMC article.
- Fact Sheet for Healthcare Providers - Emergency Use Authorization (EUA) of Remdesivir (GS-5734TM) [Internet]. U.S. Food and Drug Administration (FDA). 2020. Available from: https://www.fda.gov/media/137566/download
- Kalil AC. Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA [Internet]. 2020 Mar 24; Available from: 10.1001/jama.2020.4742 - DOI
- Wang T., Du Z., Zhu F., Cao Z., An Y., Gao Y. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet [Internet] 2020 Mar 21;395(10228):e52. doi: 10.1016/S0140-6736(20)30558-4. Available from: - DOI
- Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet] 2020;395(10223):497–506. http://www.sciencedirect.com/science/article/pii/S0140673620301835 Available from:
- Terpos E., Ntanasis-Stathopoulos I., Elalamy I., Kastritis E., Sergentanis T.N., Politou M. Hematological findings and complications of COVID-19. Am J Hematol [Internet] 2020 Apr 13 doi: 10.1002/ajh.25829. n/a(n/a). Available from: - DOI